TYRA Tyra Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1863127 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-52.1%
TTM EPS YoY-39.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-34.9%
ROA-33.0%
ROIC (approx.)-63.3%
Asset turnover—
Leverage & solvency
Liabilities / assets4.8%
Debt / equity0.00x
Current ratio23.93x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.70x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $102.93M | $80.08M |
| SG&A expense | $29.83M | $24.10M |
| Operating income | -$132.76M | -$104.18M |
| Income tax | $0 | $0 |
| Net income | -$119.95M | -$86.48M |
| EBITDA | -$132.22M | -$103.66M |
| EPS (basic) | -2.01 | -1.51 |
| EPS (diluted) | -2.01 | -1.51 |
| Weighted avg. shares (diluted) | 59.60M | 57.22M |
| Balance sheet | ||
| Cash & equivalents | $77.39M | $92.97M |
| Current assets | $265.45M | $347.46M |
| PP&E, net | $1.31M | $1.65M |
| Total assets | $282.61M | $363.56M |
| Current liabilities | $18.09M | $14.59M |
| Total liabilities | $23.43M | $20.41M |
| Shareholders' equity | $259.18M | $343.15M |
| Shares outstanding | 53.71M | 50.75M |
| Cash flow statement | ||
| Operating cash flow | -$95.14M | -$69.77M |
| Capital expenditure | $141,000 | $664,000 |
| Free cash flow | -$95.28M | -$70.44M |
| Investing cash flow | $72.46M | -$98.40M |
| Financing cash flow | $8.10M | $202.14M |
| Depreciation & amortization | $546,000 | $519,000 |
| Stock-based compensation | $28.01M | $22.80M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.